These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 36408671)
1. A Semi-mechanistic Model to Characterize the Long-Term Dynamics of Hepatitis B Virus Markers During Treatment With Lamivudine and Pegylated Interferon. El Messaoudi S; Lemenuel-Diot A; Gonçalves A; Guedj J Clin Pharmacol Ther; 2023 Feb; 113(2):390-400. PubMed ID: 36408671 [TBL] [Abstract][Full Text] [Related]
2. Peginterferon-α2a combined with response-guided short-term lamivudine improves response rate in hepatitis B e antigen-positive hepatitis B patients: a pilot study. Huang Z; Deng H; Zhao Q; Zheng Y; Peng L; Lin C; Zhao Z; Gao Z Eur J Gastroenterol Hepatol; 2013 Oct; 25(10):1165-9. PubMed ID: 23571612 [TBL] [Abstract][Full Text] [Related]
3. [Clinical efficacy of various antiviral-based strategies to treat chronic hepatitis patients with positivity for hepatitis B e antigen and rtN236T mutation]. Yue W; Yuan H; Mao XR; Deng YD; Chen L Zhonghua Gan Zang Bing Za Zhi; 2013 Mar; 21(3):184-8. PubMed ID: 23967738 [TBL] [Abstract][Full Text] [Related]
4. Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype. Sonneveld MJ; Rijckborst V; Cakaloglu Y; Simon K; Heathcote EJ; Tabak F; Mach T; Boucher CA; Hansen BE; Zeuzem S; Janssen HL Antivir Ther; 2012; 17(1):9-17. PubMed ID: 22267464 [TBL] [Abstract][Full Text] [Related]
5. Efficacy of pegylated interferon α2a in patients without HBeAg loss after the withdrawal of long-term lamivudine therapy. Zhang XQ; Zhang HY; You JP; Mao Q Virol J; 2013 Jan; 10():21. PubMed ID: 23320822 [TBL] [Abstract][Full Text] [Related]
6. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. Buster EH; Flink HJ; Cakaloglu Y; Simon K; Trojan J; Tabak F; So TM; Feinman SV; Mach T; Akarca US; Schutten M; Tielemans W; van Vuuren AJ; Hansen BE; Janssen HL Gastroenterology; 2008 Aug; 135(2):459-67. PubMed ID: 18585385 [TBL] [Abstract][Full Text] [Related]
7. [Effects of antiviral agents on intrahepatic ccc DNA in HBeAg-positive chronic hepatitis B patients]. Lu HY; Zhuang LW; Yu YY; Si CW; Li J Zhonghua Gan Zang Bing Za Zhi; 2008 Mar; 16(3):198-202. PubMed ID: 18364079 [TBL] [Abstract][Full Text] [Related]
8. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. Lau GK; Piratvisuth T; Luo KX; Marcellin P; Thongsawat S; Cooksley G; Gane E; Fried MW; Chow WC; Paik SW; Chang WY; Berg T; Flisiak R; McCloud P; Pluck N; N Engl J Med; 2005 Jun; 352(26):2682-95. PubMed ID: 15987917 [TBL] [Abstract][Full Text] [Related]
9. Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients. Yeh ML; Peng CY; Dai CY; Lai HC; Huang CF; Hsieh MY; Huang JF; Chen SC; Lin ZY; Yu ML; Chuang WL PLoS One; 2015; 10(4):e0122259. PubMed ID: 25835020 [TBL] [Abstract][Full Text] [Related]
10. A multiphase model of the dynamics of HBV infection in HBeAg-negative patients during pegylated interferon-alpha2a, lamivudine and combination therapy. Colombatto P; Civitano L; Bizzarri R; Oliveri F; Choudhury S; Gieschke R; Bonino F; Brunetto MR; Antivir Ther; 2006; 11(2):197-212. PubMed ID: 16640101 [TBL] [Abstract][Full Text] [Related]
11. Polymorphisms near IL28B and serologic response to peginterferon in HBeAg-positive patients with chronic hepatitis B. Sonneveld MJ; Wong VW; Woltman AM; Wong GL; Cakaloglu Y; Zeuzem S; Buster EH; Uitterlinden AG; Hansen BE; Chan HL; Janssen HL Gastroenterology; 2012 Mar; 142(3):513-520.e1. PubMed ID: 22108195 [TBL] [Abstract][Full Text] [Related]
12. Efficacy of granulocyte-macrophage colony-stimulating factor or lamivudine combination with recombinant interferon in non-responders to interferon in hepatitis B virus-related chronic liver disease patients. Guptan RC; Thakur V; Kazim SN; Sarin SK J Gastroenterol Hepatol; 2002 Jul; 17(7):765-71. PubMed ID: 12121506 [TBL] [Abstract][Full Text] [Related]
13. Peginterferon alfa-2b as monotherapy or in combination with lamivudine in patients with HBeAg-negative chronic hepatitis B: a randomised study. Papadopoulos VP; Chrysagis DN; Protopapas AN; Goulis IG; Dimitriadis GT; Mimidis KP Med Sci Monit; 2009 Feb; 15(2):CR56-61. PubMed ID: 19179968 [TBL] [Abstract][Full Text] [Related]
14. A viral kinetic study using pegylated interferon alfa-2b and/or lamivudine in patients with chronic hepatitis B/HBeAg negative. Sypsa VA; Mimidis K; Tassopoulos NC; Chrysagis D; Vassiliadis T; Moulakakis A; Raptopoulou M; Haida C; Hatzakis A Hepatology; 2005 Jul; 42(1):77-85. PubMed ID: 15962284 [TBL] [Abstract][Full Text] [Related]
15. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation. Shepherd J; Jones J; Takeda A; Davidson P; Price A Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047 [TBL] [Abstract][Full Text] [Related]
16. [A pilot study of peginterferon alfa-2a combined with short-term lamivudine therapy in HBeAg-positive chronic hepatitis B patients]. Huang ZL; Zhao ZX; Deng H; Zhang YF; Lu CR; Gao ZL Zhonghua Gan Zang Bing Za Zhi; 2010 Jun; 18(6):419-22. PubMed ID: 20587310 [TBL] [Abstract][Full Text] [Related]
17. HBsAg seroconversion after pegylated interferon alfa 2a rescue in a lamivudine-resistant patient with HBeAg-negative chronic hepatitis B and favourable IL28-B genotype. Stanzione M; Stornaiuolo G; Rizzo V; Pontarelli A; Gaeta GB Infez Med; 2016 Jun; 24(2):144-6. PubMed ID: 27367326 [TBL] [Abstract][Full Text] [Related]
18. HBeAg-positive chronic hepatitis B: why do I treat my patients with pegylated interferon? Kao JH Liver Int; 2014 Feb; 34 Suppl 1():112-9. PubMed ID: 24373087 [TBL] [Abstract][Full Text] [Related]
19. Extended treatment with peginterferon α-2a in combination with lamivudine or adefovir for 96 weeks yields high rates of HBeAg and HBsAg seroconversion. Cao ZH; Ma LN; Zhang HW; Liu YL; Chen XY J Dig Dis; 2013 Aug; 14(8):446-50. PubMed ID: 23615131 [TBL] [Abstract][Full Text] [Related]
20. Pretreatment with pegylated interferon prevents emergence of lamivudine mutants in lamivudine-naive patients: a pilot study. Villa E; Lei B; Taliani G; Graziosi A; Critelli R; Luongo M; Gennari W; Bianchini M; Ferretti I Antivir Ther; 2009; 14(8):1081-7. PubMed ID: 20032538 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]